GSC
NYMX

Ground Swell Capital’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Ground Swell Capital’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-202
Closed -$1K – 2856
2014
Q2 		$1K Buy
+202
New +$1.04K ﹤0.01% 1814

Other funds holding NYMX

AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
WMS Partners Towson, Maryland $1.78B AUM 11.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MCM
Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return
EVC
Eidelman Virant Capital Saint Louis, Missouri $136M AUM 15.11% 1-Year Est. Return
GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ground Swell Capital's NYMX Position: Q3 2014 in Review

Ground Swell Capital sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2014, closing a stake of 202 shares — an estimated $1K sold.

Ground Swell Capital first reported a position in NYMX in Q2 2014 and held it in 1 quarter. The position peaked at $1K in Q2 2014. 29 funds tracked by Wall St. Rank hold NYMX as of Q3 2014.

  • Ground Swell Capital reported no remaining Nymox Pharmaceutical Corp position as of Q3 2014 after selling out during the quarter.
  • Ground Swell Capital sold 202 Nymox Pharmaceutical Corp shares in Q3 2014, an estimated $1K.
  • Ground Swell Capital first reported a position in Nymox Pharmaceutical Corp in Q2 2014 and held it in 1 quarter.
  • Ground Swell Capital's Nymox Pharmaceutical Corp position peaked at $1K in Q2 2014.
  • 29 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.